Pathologic assessment of resected stage III non-small cell lung cancer after neoadjuvant chemotherapy: identification of additional prognostic factors
{{output}}
Background: Non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant chemotherapy (NACT) followed by surgery represent an ideal clinical setting to identify prognostic factors. To date, major pathological response (MPR)... ...
